SV103Vaccines
ScientiaVision Product Pinpoint: The New Vaccines
Published March 2009

ScientiaVision Product Pinpoint: The New Vaccines focuses on growth, opportunity, challenges, products, and competitors in the worldwide vaccine market. The industry has grown from primarily comprising commodity vaccines to a market that includes several blockbuster products, encompasses myriad licensing agreements with biotechnology companies, and is expanding through the creation of entirely new market segments. 

The worldwide market for vaccines has more than doubled in three years, from US$11.6 billion (€9.4 billion) in 2005 to US$25.2 billion (€16.5 billion) in 2008, having grown at a compound annual rate of 31.8% (27.6% for Euros).  The market has primarily been driven by the billion-dollar products Prevnar (Wyeth); Gardasil (Merck); Merck’s ProQuad/M-M-R II/Varivax line; GlaxoSmithKline’s Infanrx and Pediarix; GlaxoSmithKline’s hepatitis line; Sanofi Pasteur’s line of polio/whooping cough/Hib vaccines; and Sanofi Pasteur’s line of influenza vaccines.  For the forecast period, SV projects that sales will more than double again to US$50.7 billion (€34.7 billion) in 2013, reflecting compound annual growth of 21.7% (19.2% for Euros). 

This report breaks the market down by regions, as well as by product categories, with historical (2005 to 2007), base year (2008), and forecast data (2009 to 2013) for each market segment.  Market shares are provided for 2005 through 2008. All sales and market estimates are presented both in U.S. Dollars and Euros.  215 pages, 75 exhibits.

Price: $2,995.00

Format
File download

Quantity: